Knowledge Insight: Anti-Tumor Potential of Human IL‑28A Protein (IFN‑λ2)
Knowledge Insight: Anti-Tumor Potential of Human IL‑28A Protein (IFN‑λ2)
1. Core Concepts
Human interleukin‑28A (IL‑28A), also referred to as interferon‑λ2 (IFN‑λ2), is a key member of the type III interferon family. This family includes IL‑28A, IL‑28B, IL‑28C, and IL‑29.
IL‑28A signals through a heterodimeric receptor complex consisting of IL‑28Rα and IL‑10Rβ, which is mainly expressed on epithelial cells and specific immune subsets. This restricted expression pattern gives IL‑28A high tissue specificity and a more favorable safety profile compared with type I interferons.
2. Research Frontiers
Type III interferons have emerged as promising candidates for next‑generation cancer immunotherapy. Current research focuses on:
- IL‑28A‑mediated immune activation in the tumor microenvironment
- Specific anti‑tumor effects on epithelial‑derived solid tumors
- Combination strategies with immune checkpoint inhibitors
- Optimized delivery for enhanced efficacy and safety
- Preclinical validation of IL‑28A as an immunotherapeutic agent
3. Research Significance
IL‑28A exhibits unique value in oncology and immunology:
- Drives anti‑tumor immune responses without widespread systemic toxicity
- Activates innate and adaptive immunity, especially NK cells and T cells
- Enhances immune cell infiltration into tumor tissues
- Provides a safer alternative to type I interferons for clinical translation
- Supports development of targeted immunotherapies for solid tumors
High‑quality recombinant IL‑28A protein is essential for reliable mechanistic and translational studies.
4. Anti‑Tumor Mechanisms of IL‑28A
Key Immune Players
IL‑28A does not directly kill tumor cells but orchestrates systemic anti‑tumor immunity:
- NK cells: Critical for innate anti‑tumor cytotoxicity
- CD4⁺ / CD8⁺ T cells: Mediate adaptive immune clearance
- Dendritic cells: Promote antigen presentation and T‑cell priming
- Neutrophils: Participate in tumor immune surveillance
Core Mechanisms
- Promotes immune cell migration and infiltration into tumors
- Activates JAK‑STAT signaling and induces interferon‑stimulated genes (ISGs)
- Enhances anti‑tumor function of NK cells and cytotoxic T lymphocytes
- Remodels the tumor microenvironment toward immune‑active status
Advantages Over Type I Interferons
- Limited receptor distribution reduces systemic side effects
- Stronger activity in epithelial tumors (liver, lung, intestine)
- Mild safety profile observed in clinical viral infection studies
- Potential for long‑term clinical application
5. Product Empowerment by ANT BIO PTE. LTD.
ANT BIO PTE. LTD. provides Human IL‑28A Protein, His Tag (Cat. No. S0A4047) under the UA brand, a mammalian‑expressed recombinant protein designed for cancer immunology, antiviral research, and drug development.
Core Product Advantages
表格
|
Core Product Advantages |
|
High Bioactivity & Native Conformation: Expressed in mammalian cells to ensure correct folding, glycosylation, and natural biological activity. |
|
High Purity & Low Endotoxin: Purity >95% by SDS‑PAGE/HPLC; endotoxin <1.0 EU/μg, suitable for sensitive in vitro and in vivo assays. |
|
Excellent Stability & Batch Consistency: Strict quality control ensures reproducible results for long‑term studies. |
|
His‑Tag Convenience: Supports easy purification, detection, and immobilization for protein interaction assays. |
Key Applications
表格
|
Key Applications |
|
Antiviral Immunity: Study roles in HCV, HBV, influenza, and other viral infections. |
|
Tumor Immunotherapy: Investigate anti‑tumor effects and immune regulation. |
|
Inflammation & Autoimmunity: Explore immunomodulatory functions in related diseases. |
|
Drug Screening: Identify agonists, antagonists, and targeted therapeutic molecules. |
|
Signaling Pathway Research: Analyze JAK‑STAT activation and downstream ISG expression. |
6. Brand Mission
ANT BIO PTE. LTD. is a trusted provider of life science reagents, supporting researchers worldwide with high‑performance antibodies, recombinant proteins, ELISA kits, and general laboratory reagents. We operate three specialized sub‑brands:
- Absin: General reagents, buffers, and assay kits
- Starter: High‑quality antibodies for research and diagnostics
- UA: Recombinant proteins for immunization, validation, and standardization
7. Related Product List
- Human IL‑28A Protein, His tag (UA, S0A4047)
- IL‑28A / IFN‑λ ELISA kits (Absin)
- Antibodies against IL‑28A and IL‑28R (Starter)
- Immunoassay buffers and reagents (Absin)
- Other recombinant cytokines & immune proteins (UA)
Brand Promotion Copy
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.
